Taysha Gene Therapies, Inc. (TSHA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.96-1.25%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Taysha Gene Therapies, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	1.59M
EPS	—	-0.129
Annual ending 2026-12-31
Revenue	—	1.91M
EPS	—	-0.499
Annual ending 2027-12-31
Revenue	—	28.47M
EPS	—	-0.524

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain sufficient capital via debt issuance	Debt issuance provides capital for progress.	Intact	capital runs low or no further funding available in 2026	Capital raised via 32.5M share issuance in June 2026 TSHA issued 32.5M shares in June 2026, confirming access to capital markets to fund operations through 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance TSHA-102 clinical development on schedule	Taysha advances TSHA-102 clinical development with a shortened timeline.	Improving	TSHA-102 development delays or setbacks occur next year	Qualitative: PPQ completion targeted Q4 2026; FDA feedback H1 2027 TSHA-102 development is advancing as planned with PPQ completion targeted for Q4 2026 and FDA feedback in H1 2027. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce net losses from 2026-Q1 baseline	The company aims to improve financial performance despite a net loss of $42.41M in 2026-Q1.	Intact	net loss worsens or remains flat relative to -$42.41M in 2026-Q1	Net income: $-46.639M FY2026-Q2; GAAP. Published target: net loss improves from -$42.41M in 2026-Q1 over next 4 quarters. Target period is not explicitly aligned with this observation. Source published Aug 11, 2026-46,639,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: eecff138-cfb5-4ffb-99b0-44bb42c60ae1. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Increase revenue from $1.85M in 2026 to higher levels	A primary condition in Taysha Gene Therapies, Inc.'s published investment case. The stated target is revenue grows above $1.85M in FY26 and approaches $29.7M in FY27.	Broken	revenue falls below $1.85M in FY26 or fails to grow toward $29.7M in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.52

$-0.46 → $-0.52 · observed estimates

FY2027 revenue$0.03B

$0.04B → $0.03B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.46	$37,360,943	6 / 7
2026-07-25	$-0.46	$37,360,943	6 / 7
2026-07-26	$-0.46	$37,360,943	6 / 7
2026-07-27	$-0.46	$37,360,943	6 / 7
2026-07-28	Unavailable	$29,722,000	4 / 11
2026-07-29	$-0.46	$37,360,943	6 / 7
2026-07-30	$-0.46	$37,360,943	6 / 7
2026-07-31	Unavailable	$29,722,000	4 / 11
2026-08-01	$-0.46	$37,360,943	6 / 7
2026-08-02	Unavailable	$29,722,000	4 / 11
2026-08-03	$-0.46	$37,360,943	6 / 7
2026-08-04	$-0.46	$37,360,943	6 / 7
2026-08-05	Unavailable	$29,722,000	4 / 11
2026-08-06	Unavailable	$29,722,000	4 / 11
2026-08-08	$-0.46	$37,360,943	6 / 7
2026-08-09	$-0.46	$37,360,943	6 / 7
2026-08-10	$-0.46	$37,360,943	6 / 7
2026-08-12	Unavailable	$29,722,000	4 / 11
2026-08-13	$-0.46	$37,360,943	6 / 7
2026-08-14	$-0.46	$37,360,943	6 / 7
2026-08-15	$-0.46	$37,360,943	6 / 7
2026-08-16	$-0.46	$37,360,943	6 / 7
2026-08-17	$-0.46	$37,360,943	6 / 7
2026-08-18	$-0.46	$37,360,943	6 / 6
2026-08-19	$-0.46	$37,360,943	6 / 7
2026-08-20	$-0.52	$28,473,384	6 / 7
2026-08-21	$-0.52	$28,473,384	6 / 7
2026-08-22	$-0.52	$28,473,384	6 / 7
2026-08-23	$-0.52	$28,473,384	6 / 7
2026-08-24	$-0.52	$28,473,384	6 / 7
2026-08-25	$-0.52	$28,473,384	6 / 7
2026-08-26	$-0.52	$28,473,384	6 / 7
2026-08-27	$-0.52	$28,473,384	6 / 7
2026-08-28	$-0.52	$28,473,384	6 / 7
2026-08-29	$-0.52	$28,473,384	6 / 7
2026-08-30	$-0.52	$28,473,384	6 / 7
2026-08-31	$-0.52	$28,473,384	6 / 7
2026-09-01	$-0.52	$28,473,384	6 / 7
2026-09-02	$-0.52	$28,473,384	6 / 7
2026-09-03	$-0.52	$28,473,384	5 / 7
2026-09-04	$-0.52	$28,473,384	5 / 7
2026-09-05	$-0.52	$28,473,384	5 / 7
2026-09-06	$-0.52	$28,473,384	5 / 7
2026-09-07	$-0.52	$28,473,384	5 / 7
2026-09-08	$-0.52	$28,473,384	5 / 7
2026-09-09	$-0.52	$28,473,384	5 / 7
2026-09-10	$-0.52	$28,473,384	5 / 7
2026-09-11	$-0.52	$28,473,384	5 / 7
2026-09-12	$-0.52	$28,473,384	5 / 7
2026-09-13	$-0.52	$28,473,384	5 / 7
2026-09-14	$-0.52	$28,473,384	5 / 7
2026-09-15	$-0.52	$28,473,384	5 / 7
2026-09-16	$-0.52	$28,473,384	5 / 7
2026-09-17	$-0.52	$28,473,384	5 / 7
2026-09-18	$-0.52	$28,473,384	5 / 7
2026-09-19	$-0.52	$28,473,384	5 / 7
2026-09-20	$-0.52	$28,473,384	6 / 7
2026-09-21	$-0.52	$28,473,384	6 / 7
2026-09-22	$-0.52	$28,473,384	6 / 7
2026-09-23	$-0.52	$28,473,384	6 / 7
2026-09-24	$-0.52	$28,473,384	6 / 7
2026-09-25	$-0.52	$28,473,384	6 / 7
2026-09-26	$-0.52	$28,473,384	6 / 7
2026-09-27	$-0.52	$28,473,384	6 / 7
2026-09-28	$-0.52	$28,473,384	6 / 7
2026-09-29	$-0.52	$28,473,384	6 / 7
2026-09-30	$-0.52	$28,473,384	6 / 7
2026-10-01	$-0.52	$28,473,384	6 / 7
2026-10-02	$-0.52	$28,473,384	6 / 7
2026-10-03	$-0.52	$28,473,384	6 / 7
2026-10-04	$-0.52	$28,473,384	6 / 7
2026-10-05	$-0.52	$28,473,384	6 / 7
2026-10-06	$-0.52	$28,473,384	6 / 7
2026-10-07	$-0.52	$28,473,384	6 / 7
2026-10-08	$-0.52	$28,473,384	6 / 7
2026-10-09	$-0.52	$28,473,384	6 / 7
2026-10-10	$-0.52	$28,473,384	6 / 7
2026-10-11	$-0.52	$28,473,384	6 / 7
2026-10-12	$-0.52	$28,473,384	6 / 7
2026-10-13	$-0.52	$28,473,384	6 / 7
2026-10-14	$-0.52	$28,473,384	6 / 7
2026-10-15	$-0.52	$28,473,384	6 / 7
2026-10-16	$-0.52	$28,473,384	6 / 7
2026-10-17	$-0.52	$28,473,384	6 / 7
2026-10-18	$-0.52	$28,473,384	6 / 7
2026-10-19	$-0.52	$28,473,384	6 / 7
2026-10-20	$-0.52	$28,473,384	6 / 7
2026-10-21	$-0.52	$28,473,384	6 / 7
2026-10-22	$-0.52	$28,473,384	6 / 7
2026-10-23	$-0.52	$28,473,384	6 / 7
2026-10-24	$-0.52	$28,473,384	6 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	14	0	0
2026-06-01	13	0	0
2026-07-01	13	0	0
2026-08-01	12	0	0
2026-09-01	13	0	0
2026-10-01	13	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 13 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce net losses from 2026-Q1 baselineNet income: $-46.639M
Increase revenue from $1.85M in 2026 to higher levelsPublished status: Broken

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-49.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Taysha Gene Therapies, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-development company, where the business case depends on advancing a potential therapy through trials and regulatory steps. The long-term thesis is progressing but remains mixed, with management on track to fund operations into the second half of 2028 and key development milestones still ahead.

What's priced into Taysha Gene Therapies, Inc.

TSHA carries an expensive valuation versus peers, with optionality driving the valuation gap; optionality means value based on possible future outcomes that are not yet established. The evidence says the expensive valuation is not matched by a full stack of weakness and turbulence, but model confidence is low and the expectations gap is notable.

What the fundamentals likely do

Near term, weak recent financial performance and a run of earnings misses make results a key risk. Management has completed dosing in the 17-patient REVEAL pivotal trial, continues ASPIRE dosing, and expects topline data and FDA feedback on the BLA pathway in the first half of 2027; a BLA is a request for FDA approval to market a biologic medicine. Cash resources are expected to fund operations into the second half of 2028, while expanded manufacturing support and launch-related spending point to preparation rather than established commercial performance.

What Taysha Gene Therapies, Inc. hinges on

The multi-year thesis hinges on TSHA-102 data, FDA feedback, and progress on the planned BLA-enabling manufacturing campaign. A guidance cut at the next call would be a meaningful negative, while continued strength among healthcare bellwethers could support sector momentum; weakening employment data could weigh on healthcare names. Recent litigation and debt issuance are additional events to monitor, though the evidence gives limited detail on their effects.